DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin by Li, Kai et al.
                                                              
University of Dundee
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-
small cell lung cancer cells via activation of -catenin
Li, Kai; Mo, Chunfen; Gong, Di; Chen, Yan; Huang, Zhao; Li, Yanyan; Zhang, Jie; Huang,
Lugang; Li, Yuan; Fuller-Pace, Frances V.; Lin, Ping; Wei, Yuquan
Published in:
Cancer Letters
DOI:
10.1016/j.canlet.2017.02.029
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Li, K., Mo, C., Gong, D., Chen, Y., Huang, Z., Li, Y., ... Wei, Y. (2017). DDX17 nucleocytoplasmic shuttling
promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of -catenin. Cancer
Letters, 400, 194-202. https://doi.org/10.1016/j.canlet.2017.02.029
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
1DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small 1 
cell lung cancer cells via activation of β-catenin 2 
Kai Li 
a,1
, Chunfen Mo 
b, 1
, Di Gong 
a
, Yan Chen
 c
, Zhao Huang
 c
, Yanyan Li
 a
, Jie Zhang
 a
, Lugang 3 
Huang
 d
, Yuan Li
 d
, Frances V. Fuller-Pace
 e
, Ping Lin
 a, * 
and Yuquan Wei
 c
 4 
5 
a 
Lab of Experimental Oncology, State Key Laboratory of Biotherapy and Cancer Center, West 6 
China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China 7 
b 
Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, 8 
Chengdu, China 9 
c
 Lab of Cancer Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China 10 
Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China 11 
d
 Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, China 12 
e
 Division of Cancer Research, University of Dundee, Ninewells Hospital & Medical School, 13 
Dundee, UK14 
15 
1
 These authors contributed equally to this work. 16 
17 
Running title: DDX17 nucleocytoplasmic shuttling contributes to gefitinib resistance 18 
19 
Keywords: Non-small cell lung cancer, DDX17, Chemoresistance, Nucleocytoplasmic shuttle, 20 
β-catenin 21 
22 
*Revised Manuscript with track changes
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
2 
* To whom correspondence should be addressed:  23 
Ping Lin, Division of Experimental Oncology, State Key Laboratory of Biotherapy, West China 24 
Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy 25 
Tel: +86-28-85164016; Fax: +86-28-85582944; E-mail: linping@scu.edu.cn;  26 
Current Address: 1# Keyuan 4 Road, Gaopeng Avenue, Hi-tech Development, Chengdu, Sichuan, 27 
610041, P.R.China.  28 
3 
Abstract 29 
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are 30 
effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations, almost all these 31 
patients will eventually develop acquired resistance to EGFR-TKI. However, the molecular 32 
mechanisms responsible for gefitinib resistance remain still not fully understood. Here, we report 33 
that elevated DDX17 levels are observed in gefitinib-resistant NSCLC cells than gefitinib-sensitive 34 
cells. Upregulation of DDX17 enhances the gefitinib resistance, whereas DDX17-silenced cells 35 
partially restore gefitinib sensitivity. Mechanistically, we demonstrate that DDX17 disassociates 36 
the E-cadherin/β-catenin complex, resulting in β-catenin nuclear translocation and subsequently 37 
augmenting the transcription of β-catenin target genes. Moreover, we identify two nuclear 38 
localization signal (NLS) and four nuclear export signal (NES) sequences mediated DDX17 39 
nucleocytoplasmic shuttling via an exportin/importin-dependent pathways. Interruption of dynamic 40 
nucleocytoplasmic shuttling of DDX17 impairs DDX17-mediating the activation of β-catenin and 41 
acquired resistance in NSCLC cells. In conclusion, our findings reveal a novel and important 42 
mechanism by which DDX17 contributes to acquired gefitinib resistance through 43 
exportin/importin-dependent cytoplasmic shuttling and followed by activation of β-catenin, and 44 
DDX17 inhibition may be a promising strategy to overcome acquired resistance of gefitinib in 45 
NSCLC patients.  46 
4 
1. Introduction 47 
Lung cancer is one of the mostly common malignancy and the leading cause of 48 
cancer-related deaths worldwide, with a five-year overall survival rate of only 15% [1]. Patients 49 
with non-small cell lung cancer (NSCLC), which accounts for approximately 80% of all lung 50 
cancer cases, are often diagnosed at advanced stages of the disease, leading to poor prognosis 51 
in lung cancer patients [2, 3]. Recent studies have indicated that the epidermal growth factor 52 
receptor (EGFR) signalling is frequently overexpressed or aberrantly activated in NSCLC and has 53 
been as an attractive target for cancer therapy [4, 5]. Somatic mutations including in-frame 54 
deletion mutation in exon 19 and the L858R mutation in exon 21 of the EGFR gene, are 55 
associated with favorable response to the EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as 56 
gefitinib and erlotinib [6-8]. Despite good initial responses to EGFR-TKIs, most lung 57 
adenocarcinoma patients eventually develop resistance to anti-EGFR agents within 12 months 58 
through development of a secondary mutation in EGFR that reduces its binding affinity for TKIs or 59 
constitutive activation of downstream molecules to raise the compensatory survival signals [9, 10]. 60 
Overexpression or constitutive phosphorylation of HER3 can lead to significant resistance to 61 
EGFR-TKIs by activation of downstream PI3K/AKT pathways, which is independent of EGFR 62 
kinase activity [11, 12]. Moreover, abnormal activation of c-Met was significantly associated with 63 
poor response to EGFR-TKIs treatment, regardless of the EGFR status in NSCLC patients [13, 64 
14]. A randomized phase II trial has demonstrated that dual inhibition of EGFR and c-Met can 65 
overcome resistance of EGFR-TKIs and improve outcomes in the MET-positive NSCLC patients 66 
[15, 16]. However, the mechanisms responsible for intrinsic resistance and other acquired 67 
resistance to EGFR-TKI are not fully understood. 68 
5 
DEAD box helicase 17 (DDX17) belongs to the DEAD box family of RNA helicases and is a 69 
transcriptional co-regulator required for the action of diverse transcription factors that are critical 70 
for normal biologic processes as well as cancer development [17]. DDX17 coactivates oestrogen 71 
receptor alpha (ERα) and is required for oestrogen-dependent expression of ERα-responsive 72 
genes and breast cancer cell growth [18]. Furthermore, DDX17 dysregulation is associated with 73 
the tumorigenesis of meibomian cell carcinoma [19]. In mouse mammary tumor cells, DDX17 74 
regulates the alternative splicing of the chromatin-binding factor macroH2A1 histone gene, 75 
leading to transcriptional alterations to a set of genes involved in redox metabolism [20]. 76 
Additionally, DDX17 subunit in the mouse Drosha complex is indispensable for survival in mice 77 
and is required for primary miRNA and rRNA processing [21]. However, the role of DDX17 in the 78 
susceptibility to EGFR-TKIs in NSCLC cells remains unknown.  79 
In the present study, we provided the first evidence that increased expression of DDX17 in 80 
gefitinib-resistant NSCLC cells than gefitinib-sensitive NSCLC cells. DDX17 downregulation 81 
promotes the apoptosis of gefitinib-resistant NSCLC cells exposed to gefitinib, whereas DDX17 82 
overexpression protects gefitinib-sensitive NSCLC cells against this effect. Mechanistically, we 83 
demonstrate that DDX17 interacts with cytoplasmic β-catenin, facilitates the dissociation of 84 
β-catenin from the E-cadherin/β-catenin complex, enhances β-catenin nuclear accumulation, 85 
subsequently augments the transcription of β-catenin target genes, and ultimately leads to 86 
acquired resistance to gefitinib. Moreover, we found that DDX17 was a nucleocytoplasmic 87 
shuttling protein that was mediated by two NLS and four NES sequence elements. Interrupting 88 
DDX17 nucleocytoplasmic shuttling impairs DDX17-mediated activation of β-catenin and 89 
resistance to gefitinib in NSCLC cells. Taken together, our study highlights the significance of 90 
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DDX17 in gefitinib-resistant NSCLC and implicates DDX17 as a potential therapeutic target to 91 
enhance the efficacy of gefitinib in NSCLC patients. 92 
 93 
2. Materials and Methods 94 
2.1 Cell culture and establishment of gefitinib resistant cell lines 95 
A431 and A431-GR cell lines were gifts from Prof. Zeng Cai (Sichuan Provincial 96 
People’s Hospital, China). A549 and A549-GR cell lines were gifts from Prof. Feng Bi 97 
(Sichuan University, China). HCC827 and PC9 NSCLC cell lines were maintained at 37°C and 5% 98 
CO2 in RPMI 1640 supplemented with 10% fetal bovine serum (Gibco) and 100 units/ml penicillin, 99 
and 100 mg/ml streptomycin. To establish gefitinib resistant cell lines, parental cells were exposed 100 
to gradually elevated concentrations of gefitinib for two months as reported previously [13, 22].  101 
  102 
2.2 Reagents 103 
Gefitinib and XAV-939 were purchased from Selleck chemicals, and recombinant human 104 
EGF was purchased from PeproTech. The primary antibodies included AKT (Cell signalling 105 
Technology, #4691), p-AKT (Ser473) (Cell signalling Technology, #4060), cleaved caspase-3 (Cell 106 
Signaling Technology, #9664), cleaved PARP (Cell signalling Technology, #5625), DDX17 (Santa 107 
Cruz Biotechnology, sc-271112), E-cadherin (Abcam, ab1416), EGFR (Cell signalling 108 
Technology, #4267), p-EGFR (Tyr1068) (Cell signalling Technology, #3777), ERK (Cell 109 
signalling Technology, #9102), p-ERK (Thr202/Tyr204) (Cell signalling Technology, #4370), Flag 110 
(Cell signalling Technology, #8146), Ki67 (Abcam, ab15580), KPNA1 (Sangon Biotech, D154120), 111 
KPNB1 (Sangon Biotech, D161792), PCNA (Santa Cruz Biotechnology, sc-56), XPO1 (Sangon 112 
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Biotech, D221884), α-Tubulin (Santa Cruz Biotechnology, sc-5286), β-actin (Santa Cruz 113 
Biotechnology, sc-47778), β-catenin (Abcam, ab32572), p-β-Catenin (Ser33/37/Thr41) (Cell 114 
signalling Technology, #9561).  115 
 116 
2.3 Stable cell line generation for DDX17 knockdown or overexpression  117 
The DDX17 lentiviral expression vector was constructed by inserting expanded DDX17 cDNA 118 
(NM_006386.4) fragments into a lentiviral shuttle vector. DDX17 knockdown was accomplished 119 
using a specific shRNA targeting DDX17. The shRNA sequences were as follows: shRNA-DDX17, 120 
5’-CAA GGG UAC CGC CUA UAC C-3’; shRNA-NC, 5’-TTC TCC GAA CGT GTC AGG T-3’. The 121 
packing and purification of the recombinant lentiviral vector were performed by the GenePharma 122 
Company (Shanghai, China). The indicated NSCLC cells infected with the recombinant lentiviral 123 
vectors were selected with puromycin for 2 weeks. 124 
 125 
2.4 RNA extraction and real-time PCR  126 
Total RNA was extracted using RNAiso Plus (TAKARA) according to the manufacturer’s 127 
instructions. Real-time PCR was performed with SYBR
®
 Premix Ex Taq™ II (TAKARA) using an 128 
iCycler iQ
TM
 Multicolor Real-Time Detection System (BIO-RAD) as previously described [23, 24]. 129 
The following primers were used: DDX17 forward 5’-GAACATCCGGAAGTAGCAAGG-3’, reverse 130 
5’-GATCCATCAACACATCCATTACATAT-3’; GAPDH forward 5’-ACCACAGTCCATGCCATCAC-3’, 131 
reverse 5’-TCCACCACCCTGTTGCTGTA-3’. The relative expression levels were determined 132 
using Gene Expression Macro Version 1.1 software (BIO-RAD). 133 
 134 
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2.5 TOP/FOP flash assay 135 
For cotransfection, the indicated NSCLC cells were transfected with TOPflash plasmid plus 136 
pRL-TK plasmid or FOPflash plasmid plus pRL-TK plasmid in 48-well plates. Twenty-four hours 137 
post-transfection, the cells were rinsed twice with PBS and then lysed in Passive Lysis Buffer, and 138 
the dual-luciferase reporter assay was performed according to the manufacturer’s instructions 139 
(Promega) using a Multi-Mode Microplate Reader (Synergy 2, BioTek). 140 
 141 
2.6 In vivo assays for tumor growth  142 
Female BALB/c nude mice (6-week-old) were raised in specific pathogen-free conditions. 143 
Animal care and experimental protocols were in accordance with guidelines established by the 144 
Institutional Animal Care and Use Committee of Sichuan University. The indicated NSCLC cells 145 
were suspended in 150 μL serum-free DMEM and implanted subcutaneously into the right flanks 146 
of nude mice. When subcutaneous tumor reached approximately 100 mm
3
, the tumor-bearing 147 
mice were treated with gefitinib (10 mg/kg/day, by a gavage) for 15 days. The tumor volumes were 148 
measured by calipers every 3 days, and calculated using the following formula: tumor volume 149 
(mm
3) = π/6 × length × width2.  150 
  151 
2.7 Statistical analysis 152 
All the experiments were performed at least three times independently, and all data are 153 
expressed as “mean ± SD”. A one-way ANOVA test was used to analyse quantitative data 154 
between groups. The data were analyzed using SPSS statistical software version 22.0. P < 0.05 155 
was considered statistically significant. 156 
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 157 
3. Results 158 
3.1 Upregulation of DDX17 correlates with gefitinib resistance in NSCLC cells 159 
To explore the role of DDX17 in the acquired resistance to gefitinib, we first evaluated the 160 
expression of DDX17 in different NSCLC cell lines. As shown in Figure 1A, the level of DDX17 161 
was markedly higher in gefitinib-insensitive NSCLC cell lines (PC9-GR and HCC827-GR) than 162 
that in gefitinib-sensitive NSCLC cell lines (PC9 and HCC827), respectively. A similar pattern of 163 
increased DDX17 expression level was observed in A549-GR and A431-GR cells compared 164 
with their parental A549 and A431 cells (Supplementary Figure S1). These data suggest that 165 
DDX17 may be positively correlated with gefitinib resistance in NSCLC cells. Next, we engineered 166 
stable upregulation of DDX17 expression in gefitinib-sensitive PC9 and HCC827 cells, and stable 167 
shRNA-mediated knockdown of DDX17 in gefitinib-insensitive PC9-GR and HCC827-GR cells 168 
(Figure 1B and Supplementary Figure S2A). Enforced DDX17 expression significantly increased 169 
the cell viability of PC9 and HCC827 cells in response to gefitinib (Figure 1C), whereas 170 
DDX17-silenced cells partially restored gefitinib sensitivity of PC9-GR and HCC827-GR cells 171 
(Supplementary Figure S2B). Moreover, upregulated DDX17 enhanced the resistance to 172 
gefitinib in PC9 and HCC827 cells compared to negative controlled cells (Figure 1D). Consistent 173 
with the MTT assay results, the colony formation in DDX17 overexpression NSCLC cells was 174 
significantly more compared to Mock cells (Figure 1E). The converse results were observed in 175 
DDX17-deficient NSCLC cells (Supplementary Figure S2C). Gefitinib treatment reduced 176 
p-EGFR and downstream signaling proteins p-Akt and p-ERK expressions, and meanwhile 177 
increased the levels of two apoptosis markers, cleaved caspase 3 and cleaved PARP 178 
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(Figure 1F). However, the upregulation of DDX17 partially overcame the gefitinib-inhibited 179 
EGFR, AKT and ERK activation, and suppressed cell apoptosis (Figure 1F). Conversely, 180 
knockdown of DDX17 caused decreased phosphorylation of EGFR, AKT and ERK, while 181 
increased expression of cleaved caspase 3 and cleaved PARP in gefitinib-resistant NSCLC 182 
cells treated with gefitinib (Supplementary Figure S2D). Taken together, our data indicate that 183 
DDX17 contributes to the development of acquired drug resistance to gefitinib in NSCLC cells. 184 
 185 
3.2 DDX17 disassociates the E-cadherin/β-catenin complex and promotes β-catenin nuclear 186 
translocation  187 
Recent evidence indicates that constitutive activation of Wnt/β-catenin signalling is 188 
associated with the acquired drug resistance to EGFR-TKIs in NSCLC [25-27]. To understand the 189 
molecular mechanism by which DDX17 promotes gefitinib resistance, we explored the effect of 190 
DDX17 on the nuclear translocation and activation of β-catenin. As shown in Figure 2A, 191 
β-catenin was located primarily in the plasma membrane in Mock PC9 cells; however, 192 
upregulated DDX17 led to the nuclear accumulation of β-catenin. Next, we evaluated the 193 
phosphorylation status of β-catenin. Consistently, phosphorylation of the residues that 194 
target β-catenin for proteasomal degradation (S33/S37/T41) was reduced in response to 195 
DDX17 overexpression (Figure 2B). Conversely, DDX17 knockdown significantly inhibited the 196 
levels of nuclear β-catenin in PC9-GR cells (Figure 2C). EGF, a potent activator of Wnt/β-catenin 197 
signalling as described previously [28-30], promotes β-catenin nuclear translocation in PC9-GR 198 
cells, however, DDX17 deletion markedly repressed the increased nuclear accumulation of 199 
β-catenin induced by EGF (Figure 2C). TOP/FOP-Flash assay showed that down-regulation of 200 
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DDX17 impaired the transcriptional activity of β-catenin/T-cell factor (TCF) complex regardless of 201 
EGF treatment (Figure 2D). Moreover, we found increased nuclear localization of β-catenin 202 
as well as decreased p-β-catenin (S33/S37/T41) in PC9-GR cells compared with PC9 cells 203 
(Supplementary Figure S3). Beta-catenin bound to the E-cadherin/catenin adhesion complex is 204 
mainly localizes to cell-cell adherent junctions at membranes lacking Wnt signalling, and Wnt 205 
signalling promotes the disassociation of E-cadherin/β-catenin complex and subsequently 206 
β-catenin nuclear translocation. Therefore, we next assessed whether DDX17 influenced 207 
E-cadherin/β-catenin complex stability. As shown in Figure 2E, overexpression of DDX17 208 
downregulated E-cadherin/β-catenin complex formation, whereas knockdown of DDX17 209 
augmented the association of β-catenin and E-cadherin. Considering the role of DDX17 in the 210 
nuclear accumulation and activation of the β-catenin, we next explored whether DDX17 can 211 
interact with β-catenin. Reciprocal immunoprecipitation studies revealed that endogenous DDX17 212 
bound to endogenous β-catenin directly (Figure 2F). Moreover, increased interaction between 213 
DDX17 and β-catenin was observed in response to EGF stimulus, whereas EGF repressed 214 
β-catenin binding to E-cadherin (Figure 2G). Notably, we found that DDX17 predominantly 215 
interacted with β-catenin in the cytoplasm and that EGF enhanced both the cytoplasmic and 216 
nuclear interaction of β-catenin with DDX17 in a time-dependent manner (Figure 2H). To further 217 
investigate whether DDX17-regulated gefitinib resistance involves β-catenin activation, a 218 
specific Wnt/β-catenin signalling pathway inhibitor (XAV-939) was used. XAV-939 treatment 219 
effectively reversed DDX17-induced gefitinib resistance in PC9 and HCC827 cells (Figure 220 
2I), leading to the increased levels of cleaved caspase 3 and cleaved PARP (Figure 2J). 221 
These data indicate that elevated DDX17 level leads to release and nuclear translocation of 222 
12 
β-catenin from the E-cadherin/β-catenin complex and thereby resulting in the activation of 223 
Wnt/β-catenin signalling and acquired resistance to gefitinib.  224 
 225 
3.3 Two NLSs mediated DDX17 nuclear transport by an importin-dependent pathway 226 
Because DDX17 interacted with β-catenin in the cytoplasm and nucleus, we presumed that 227 
DDX17 might be a nucleocytoplasmic shuttling protein. To test this hypothesis, we first examined 228 
the sublocalization of DDX17 in PC9 and PC9-GR cells using an immunofluorescence assay. 229 
Interestingly, DDX17 was predominantly localized to the nucleus in PC9 cells, whereas DDX17 230 
was present in the cytoplasm and nucleus in PC9-GR cells (Supplementary Figure S2A). 231 
Immunoblotting analysis also showed that more DDX17 was accumulated in both the cytoplasmic 232 
and nuclear fractions of PC9-GR cells than of PC9 cells (Supplementary Figure S2B). These 233 
results indicate that DDX17 may be a nucleocytoplasm shuttling protein.  234 
Most nucleocytoplasm shuttling proteins carry sequence elements of both nuclear 235 
localization signal (NLS) and (nuclear exporting signal) NES. We analysed the DDX17 amino acid 236 
sequence and identified two putative NLSs based on cNLS Mapper analysis 237 
(http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) (Figure 3A). Because the 238 
classical NLSs rich in basic amino acids are known as NLSs recognized by importin, we 239 
generated mutations in NLS1 (K50A, K53A, R74A, R75A, K76A and K77A) or NLS2 (K349A, 240 
R350A and R351A) of DDX17 fused with a GFP fluorescent protein. As shown in Figure 3B, the 241 
DDX17-WT protein showed both cytoplasmic and nuclear fluorescence. However, the NLS 1 242 
mutant showed strong cytoplasmic fluorescence, and the NLS 2 mutant exhibited a complex 243 
distribution in both the nucleus and cytoplasm (Figure 3B). Moreover, no significant nuclear 244 
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localization of DDX17 was observed in NLS mutant (NLS M, mutated both NLS 1 and NLS 2) 245 
(Figure 3B). The similar result was also confirmed by immunoblot analyses (Figure 3C). As the 246 
nuclear transport of most nucleocytoplasmic proteins is mediated by importin complex which 247 
formed a hetero-dimer, we next explored whether DDX17 interacts with importin. Reciprocal 248 
immunoprecipitation studies revealed that endogenous DDX17 co-precipitated with endogenous 249 
KPNA1 (also known as Importin subunit alpha-5) and KPNB1 (also known as Importin subunit 250 
beta-1) (Figure 3D). However, DDX17 NLS mutant did not co-precipitate with KPNA1 and KPNB1 251 
(Figure 3E). To further determine whether importin signalling mediated DDX17 nuclear 252 
localization, we treated cells with Ivermectin, which is a potent inhibitor of importin α/β-dependent 253 
transport [31, 32]. As shown in Figure 3F, ivermectin treatment caused the main cytoplasmic 254 
fluorescence of GFP-DDX17 fusion protein. Similarly, immunoblot analysis also showed the 255 
decreased nuclear accumulation of DDX17 in the presence of ivermectin (Figure 3G). Notably, 256 
ivermectin blocked the association of DDX17 with importin complex (Figure 3H). These data 257 
indicate that two NLSs of DDX17 recognized by importin complex mediated DDX17 nuclear 258 
transport.  259 
 260 
3.4 Four NESs mediated DDX17 nuclear export by an exportin-dependent pathway 261 
For the classical nuclear export pathway, XPO1 binds directly hydrophobic residue-rich 262 
NES sequence in the cargo protein and directs the export of the complex from the nucleus [33]. 263 
According to this theory, we found four putative NESs in DDX17 and constructed a series of site 264 
directed mutagenesis fused to the C-terminus of GFP (Figure 4A). As shown in Figure 4B, both 265 
cytoplasmic and nuclear localizations of DDX17-WT protein were observed in PC9 cells. The NES 266 
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1 mutant (L144A, L147A, L148A, I151A, V152A and I154A), NES 2 mutant (L226A, I227A, F229A, 267 
L230A, L237A, L243A, V244A, L245A) and NES 3 mutant (V284A, L284A, L292A, Y295A, I298A, 268 
L303A, L305A) showed major nuclear localization, whereas mutations on NES 4 (L448A, L454A, 269 
I455A, V457A, L458A) localized in dispersed subnuclear speckles (Figure 4B). In addition, a 270 
complete NES mutant (mutated all four NESs) resulted in exclusive nuclear localization of DDX17, 271 
suggesting that these four NESs function as DDX17 nuclear export signals (Figure 4B). 272 
Immunoblot analysis also confirmed the subcellular localization of DDX17-WT and DDX17 NES 273 
mutant (Figure 4C). To confirm the effects of XPO1 on export of DDX17, we probed the interaction 274 
between DDX17 and XPO1 via co-immunoprecipitation. It was clear that endogenous DDX17 275 
co-immunoprecipitated with endogenous XPO1 (Figure 4D). In addition, we found that the DDX17 276 
NES mutant impaired the binding of DDX17 and XPO1 (Figure 4E). To further verify that the 277 
DDX17 cytoplasmic shuttling is mediated by XPO1, PC9 cells were treated with leptomycin B 278 
(LMB), a potent and specific nuclear export inhibitor. LMB effectively suppressed the level of 279 
cytoplasmic DDX17 in PC9 cells (Figures 4F and 4G). Moreover, LMB treatment significantly 280 
disrupted the interaction between DDX17 and XPO1 (Figure 4H). These observations suggest 281 
that four NESs are required for DDX17 cytoplasmic shuttling mediated by the classical 282 
exportin-dependent pathway.  283 
 284 
3.5 The integrity of DDX17 nucleocytoplasmic shuttling is indispensable for mediating the 285 
acquired resistance and activation of β-catenin 286 
We next evaluated the impact of DDX17 nucleocytoplasmic shuttling on cellular resistance 287 
to gefitinib. As shown in Figure 5A, ectopic expression of DDX17-WT significantly increased the 288 
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cell viability of PC9 and HCC827 cells upon gefitinib treatment. The decreased resistances to 289 
gefitinib were observed in DDX17-NLS mutant and DDX17-NES mutant PC9 cells compared to 290 
DDX17-WT PC9 cells, respectively (Figure 5A). Interestingly, DDX17-NLS mutant PC9 cells 291 
showed a similar sensitivity as mock PC9 cells, whereas DDX17-NES mutant PC9 cells were 292 
more resistant to gefitinib than mock PC9 cells (Figure 5A). Consistently, less colony formations 293 
were found in DDX17-NLS mutant and DDX17-NES mutant PC9 cells than DDX17-WT PC9 cells 294 
(Figure 5B). The immunoblotting test showed that cleaved caspase 3 and cleaved PARP were 295 
significantly enhanced in both DDX17-NLS mutant and DDX17-NES mutant PC9 cells compared 296 
to DDX17-WT PC9 cells (Figure 5C). To further determine the effect of DDX17 nucleocytoplasmic 297 
shuttling on the gifitinib resistance in vivo, indicated PC9 cells were injected subcutaneously into 298 
the flanks of BALB/c nude mice. Overexpression of DDX17-WT exerted obvious gefitinib 299 
insensitivity in tumor xenografts model compared to mock xenografts in the present of gefitinib (10 300 
mg/kg per day, gavaged orally) (Figure 5D). However, DDX17-NLS mutant and DDX17-NES 301 
mutant xenografts was partially rescued gefitinib sensitivity compared with DDX17-WT xenografts 302 
(Figure 5D). The primary tumors from the DDX17-WT xenografts exhibited increased expression 303 
of Ki67 while decreased expression of cleaved caspase 3 compared with tumors originating from 304 
DDX17-NLS mutant and DDX17-NES mutant xenografts (Figure 5E).  305 
Based on the aforementioned observations, we became interested in exploring the effect of 306 
DDX17 nucleocytoplasmic shuttling on the activation of β-catenin. As shown in Figure 6A, DDX17 307 
NLS mutant showed a comparable association of β-catenin, whereas DDX17 NES mutant 308 
showed a slightly decreased association of β-catenin compared with DDX17 WT. DDX17 WT and 309 
DDX17 NLS mutant caused significant disassociation of E-cadherin/β-catenin complex, however, 310 
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DDX17 NES mutant displayed modest inhibition of the interaction between β-catenin and 311 
E-cadherin compared to control (Figure 6B). Moreover, less nuclear β-catenin was observed in 312 
the DDX17 NLS mutant and NES mutant group compared to that of the wild type (Figure 6C). In 313 
addition, DDX17 NLS mutant and NES mutant groups showed significantly decreased luciferase 314 
activity compared to wild type (Figure 6D). Overall, the above experiments suggest that 315 
interruption of DDX17 nucleocytoplasmic shuttling impairs DDX17-mediating the acquired 316 
resistance and activation of β-catenin in NSCLC cells.  317 
 318 
4. Discussion 319 
EGFR-mutant NSCLC patients who benefited from EGFR-TKI eventually develop acquire 320 
resistance to these therapies and the median duration of response is about 10 to 14 months [34, 321 
35]. Although accumulating studies revealed that a variety of mechanisms can stimulate acquired 322 
resistance to EGFR-TKI including secondary mutations within EGFR at position T790, activation 323 
of parallel receptor tyrosine kinases (such as ALK, MET and RET), and mutation or upregulation 324 
of EGFR effector proteins [36-38], the mechanisms responsible for acquired resistance to 325 
EGFR-TKIs are still large unknown. In this study, we showed that DDX17 levels were 326 
increased in gefitinib resistant cells compared with gefitinib sensitive cells. Overexpression 327 
of DDX17 significantly increased tolerance of PC9 and HCC827 cells in the present of gefitinib, 328 
whereas DDX17 suppression resulted in reduced cell viability of gefitinib-resistant PC9-GR and 329 
HCC827-GR cells. These data revealed that DDX17 expression was associated with tumor 330 
sensitivity to gefitinib in NSCLC cells.  331 
The Wnt/β-catenin signaling is one of the most critical signaling transduction pathways 332 
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during embryonic development and the stemness maintenance, and has become a hot topic in 333 
tumor research [39, 40]. In recent years, accumulating evidence reported that Wnt/β-catenin 334 
signalling has been implicated in the chemoresistance of varied cancers [41, 42]. Here, we 335 
demonstrated that DDX17 directly bound and dissociated the E-cadherin/β-catenin complex to 336 
release β-catenin, subsequently leading to β-catenin nuclear accumulation. Moreover, we found 337 
that EGF augmented the interaction between β-catenin and DDX17 both in the cytoplasm and 338 
nucleus, whereas DDX17 repression abolished the EGF-induced nuclear translocation and 339 
activation of β-catenin. Therefore, we postulated that DDX17-dependent nuclear accumulation of 340 
β-catenin released from the E-cadherin/β-catenin adhesion complex was an important 341 
mechanism driving acquired resistance to gefitinib in NSCLC cells.  342 
To enhance cytoplasmic β-catenin nuclear translocation, DDX17, which is predominantly 343 
localized in the nucleus [43], must shuttle to the cytoplasm. Interestingly, increased DDX17 levels 344 
were observed in both the cytoplasmic and nuclear fractions of PC9-GR cells than of PC9 cells. 345 
Moreover, DDX17 interacted with β-catenin both in the cytoplasm and nucleus. These data 346 
supported DDX17 as a nucleocytoplasmic protein. Most nucleocytoplasmic protein movement 347 
through the nuclear pore complex is mediated by a nuclear receptor system [44, 45]. In this study, 348 
we identified two NLSs and four NESs required for DDX17 nucleocytoplasmic shuttling. Mutation 349 
of the NLSs significantly inhibited the DDX17 nuclear localization and association of DDX17 and 350 
import complex. Analogously, NESs mutant caused nuclear accumulation of DDX17 and 351 
disrupted the interaction between DDX17 and XPO1. These results indicated that the 352 
nucleocytoplasmic shuttling of DDX17 followed a classical exportin/importin-dependent pathway. 353 
Interestingly, several DEAD box RNA helicases shuttle between the nucleus and cytoplasm via 354 
18 
XPO1-dependent nuclear export pathway, including DDX3, DDX25, and DDX48 [46-48]. 355 
Furthermore, block of DDX17 nucleocytoplasmic shuttling significantly reduced DDX17-mediated 356 
activation of β-catenin and gefitinib sensitivity in NSCLC cells, suggesting that dynamic 357 
nucleocytoplasmic shuttling of DDX17 is essential for its function. Interestingly, a decreased 358 
tolerance was observed in DDX17-NES mutant cells compared with DDX17-WT cells, however, 359 
DDX17-NES mutant cells were more resistant to gefitinib than mock PC9 cells. Because DDX17 360 
can act as co-transcriptional regulator, one possible explanation is that nuclear DDX17 regulated 361 
the transcription of target genes that lead to the activation of Wnt/β-catenin signalling independent 362 
cytoplasmic function of DDX17. Although DDX17-NLS mutant has no significant effect on the 363 
association of DDX17 and β-catenin, the nuclear accumulation of β-catenin was depressed in 364 
DDX17-NLS mutant cells compared with DDX17-WT cells. Considering the main interaction of 365 
DDX17 and β-catenin in the cytoplasm, we presume that DDX17 might function as a ‘chaperone’ 366 
to aid β-catenin nuclear import; however, the detailed mechanism requires further exploration.  367 
In summary, our study provides the first evidence that upregulated DDX17 expression is 368 
associated with gefitinib resistance in NSCLC cells and DDX17 is a nucleocytoplasmic protein 369 
mediated by two NLSs and Four NESs. We demonstrate a new molecular mechanism by which 370 
the exportin/importin-dependent nucleocytoplasmic translocation of DDX17 disassociates the 371 
E-cadherin/β-catenin complex, resulting in β-catenin nuclear translocation and subsequently 372 
augmenting the transcription of β-catenin target genes, ultimately driving gefitinib resistance in 373 
NSCLC cells. Interruption of dynamic nucleocytoplasmic shuttling of DDX17 impairs 374 
DDX17-mediating the activation of β-catenin and acquired resistance in NSCLC cells. In 375 
conclusion, we propose that DDX17 is an attractive and potential target for overcoming gefitinib 376 
19 
resistance in NSCLC therapy 377 
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8. FIGURE LEGENDS 552 
8.1 Figure 1. Upregulated DDX17 is associated with gefitinib resistance in human NSCLC 553 
cells. (A) Quantitative real-time PCR and immunoblot analysis of DDX17 expression in gefitinib 554 
sensitive and insensitive NSCLC cells. (B) Quantitative real-time PCR and immunoblot analysis 555 
showed the successful lentiviral infections of DDX17 in PC9 and HCC827 cells. (C) Stably 556 
expressing DDX17 or mock NSCLC cells were treated with 1 μM gefitinib for indicated time and 557 
analyzed for cell viability by MTT assay. (D) Effect of DDX17 overexpression on gefitinib efficacy 558 
in HCC827 and PC9 cells was detected by MTT assay. (E) Representative photographs of the 559 
colony formation of indicated NSCLC cells treated with gefitinib for 14 days after culture of cells. 560 
(F) The indicated NSCLC cells were treated with or without gefitinib and then subjected to 561 
immunoblot analysis using the indicated antibodies. Data represent the mean ± standard 562 
deviation (SD). Each experiment was performed at least in triplicate, producing consistent results. 563 
*P < 0.05. 564 
 565 
8.2 Figure 2. DDX17 disassociates the E-cadherin/β-catenin complex and promotes 566 
β-catenin nuclear translocation. (A) Immunofluorescence analysis of β-catenin (red) in 567 
indicated PC9 cells. Merged images represent overlays of β-catenin (red) and nuclear 568 
staining by DAPI (blue). (B) Immunoblotting for phosphorylated β-catenin (S33/S37/T41) in 569 
indicated PC9 cells. (C) Immunoblotting for β-catenin in the nuclear extracts of indicated 570 
PC9-GR cells in the present of EGF. PCNA was used as the control. (D) TOP/FOP flash assay in 571 
the indicated PC9-GR cells treated with or without EGF. (E) The effect of DDX17 on the 572 
association of β-catenin with E-cadherin was detected by western blot analysis. (F) The 573 
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endogenous interaction of DDX17 and β-catenin was detected by immunoprecipitation with 574 
indicated antibodies. (G) The impact of EGF on the interaction of DDX17 and 575 
β-catenin/E-cadherin complex. (H) The cytoplasmic and nuclear extracts of PC9-GR cells 576 
stimulated with EGF were isolated. Immunoprecipitation were performed with anti-DDX17 577 
antibody. α-Tubulin and PCNA were control. (I) Effect of XAV-939 on gefitinib efficacy in 578 
indicated NSCLC cells was detected by MTT assay. (J) The indicated NSCLC cells were 579 
treated with gefitinib in the presence or absence of XAV-939, and then subjected to 580 
immunoblot analysis using the indicated antibodies. Data represent the mean ± SD of three 581 
independent experiments. *P < 0.05. 582 
 583 
8.3 Figure 3. Two NLSs mediated DDX17 nuclear transport by an importin-dependent 584 
pathway. (A) Putative sequence segments of DDX17 NLSs. (B) Representative of fluorescent 585 
microscopy images show the localizations of the exogenously expressed DDX17 wild type (WT) 586 
and putative NLSs mutants fused with GFP in PC9 cells. (C) The levels of exogenously expressed 587 
DDX17 WT or NLS mutant in the extracts made from the cytoplasm or the nucleus of PC9 cells 588 
were examined by immunoblotting analysis. PCNA and α-Tubulin were used as the control. (D) 589 
The endogenous association of DDX17 and importin complex was detected by 590 
immunoprecipitation with indicated antibodies. (E) The impact of NLS mutant on the interaction 591 
between DDX17 and importin complex. (F) Representative of fluorescent microscopy images 592 
show the sub-localizations of DDX17 in PC9 cells treated with or without ivermectin. (G) The 593 
effect of Ivermectin on the distribution of DDX17 was performed by western blot analysis in PC9 594 
cells. (H) The effect of Ivermectin on the binding of DDX17 and importin complex. Data represent 595 
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the mean ± SD of three independent experiments. 596 
 597 
8.4 Figure 4. Four NESs mediated DDX17 nuclear export by an exportin-dependent pathway. 598 
(A) Putative sequence segments of DDX17 NESs. (B) Representative of fluorescent microscopy 599 
images show the localizations of the exogenously expressed DDX17 WT and putative NESs 600 
mutants fused with GFP in PC9 cells. (C) Immunoblotting for DDX17 in PC9 cytoplasmic and 601 
nuclear extracts of cells transfected with the indicated plasmids. PCNA and α-Tubulin were used 602 
as the control. (D) The endogenous association of DDX17 and XPO1 was detected by 603 
immunoprecipitation with indicated antibodies. (E) The impact of NES mutant on the interaction 604 
between DDX17 and XPO1. (F) Representative of fluorescent microscopy images show the 605 
sub-localizations of DDX17 in PC9 cells treated with or without LMB. (G) The effect of LMB on the 606 
distribution of DDX17 was performed by western blot analysis in PC9 cells. (H) The effect of LMB 607 
on the binding of DDX17 and XPO1. Data represent the mean ± SD of three independent 608 
experiments. 609 
 610 
8.5 Figure 5. Interruption of DDX17 nucleocytoplasmic shuttling impairs DDX17-mediated 611 
gefitinib resistance in vitro and in vivo. (A) Indicated NSCLC cells were treated with varied 612 
concentration of gefitinib, and the cell viability were analysed by MTT assay. (B) Representative 613 
photographs of the colony formation of indicated NSCLC cells treated with gefitinib for 14 days 614 
after culture of cells. (C) The indicated NSCLC cells were treated with gefitinib and then subjected 615 
to immunoblot analysis using the indicated antibodies. (D) The indicated NSCLC cells were 616 
transplanted into nude mice. When subcutaneous tumor reached approximately 100 mm
3
, the 617 
31 
tumor-bearing mice were treated with gefitinib (10 mg/kg/day, by a gavage) for 15 days. The 618 
tumor volumes were measured by calipers every 3 days. (E) Tumor xenograft tissues were fixed 619 
with 4% paraformaldehyde, processed, embedded in paraffin wax and then assessed for 620 
immunohistochemical analyses with indicated antibodies. Data represent the mean ± SD of three 621 
independent experiments. *P < 0.05.  622 
 623 
8.6 Figure 6. The integrity of DDX17 nucleocytoplasmic shuttling is essential for 624 
DDX17-mediating the activation of β-catenin in NSCLC cells. (A) The impact of NLS mutant 625 
and NES mutant on the interaction of DDX17 and β-catenin. (B) The effect of NLS mutant and 626 
NES mutant on the association of E-cadherin/β-catenin complex. (C) Immunoblotting for β-catenin 627 
in the nuclear extracts of indicated PC9 cells. PCNA was used as the control. (D) TOP/FOP flash 628 
assay were performed in the indicated PC9 cells. Data represent the mean ± SD of three 629 
independent experiments. *P < 0.05. 630 
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3 
Abstract 29 
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are 30 
effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations, almost all these 31 
patients will eventually develop acquired resistance to EGFR-TKI. However, the molecular 32 
mechanisms responsible for gefitinib resistance remain still not fully understood. Here, we report 33 
that elevated DDX17 levels are observed in gefitinib-resistant NSCLC cells than gefitinib-sensitive 34 
cells. Upregulation of DDX17 enhances the gefitinib resistance, whereas DDX17-silenced cells 35 
partially restore gefitinib sensitivity. Mechanistically, we demonstrate that DDX17 disassociates 36 
the E-cadherin/β-catenin complex, resulting in β-catenin nuclear translocation and subsequently 37 
augmenting the transcription of β-catenin target genes. Moreover, we identify two nuclear 38 
localization signal (NLS) and four nuclear export signal (NES) sequences mediated DDX17 39 
nucleocytoplasmic shuttling via an exportin/importin-dependent pathways. Interruption of dynamic 40 
nucleocytoplasmic shuttling of DDX17 impairs DDX17-mediating the activation of β-catenin and 41 
acquired resistance in NSCLC cells. In conclusion, our findings reveal a novel and important 42 
mechanism by which DDX17 contributes to acquired gefitinib resistance through 43 
exportin/importin-dependent cytoplasmic shuttling and followed by activation of β-catenin, and 44 
DDX17 inhibition may be a promising strategy to overcome acquired resistance of gefitinib in 45 
NSCLC patients.  46 
4 
1. Introduction 47 
Lung cancer is one of the mostly common malignancy and the leading cause of 48 
cancer-related deaths worldwide, with a five-year overall survival rate of only 15% [1]. Patients 49 
with non-small cell lung cancer (NSCLC), which accounts for approximately 80% of all lung 50 
cancer cases, are often diagnosed at advanced stages of the disease, leading to poor prognosis 51 
in lung cancer patients [2, 3]. Recent studies have indicated that the epidermal growth factor 52 
receptor (EGFR) signalling is frequently overexpressed or aberrantly activated in NSCLC and has 53 
been as an attractive target for cancer therapy [4, 5]. Somatic mutations including in-frame 54 
deletion mutation in exon 19 and the L858R mutation in exon 21 of the EGFR gene, are 55 
associated with favorable response to the EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as 56 
gefitinib and erlotinib [6-8]. Despite good initial responses to EGFR-TKIs, most lung 57 
adenocarcinoma patients eventually develop resistance to anti-EGFR agents within 12 months 58 
through development of a secondary mutation in EGFR that reduces its binding affinity for TKIs or 59 
constitutive activation of downstream molecules to raise the compensatory survival signals [9, 10]. 60 
Overexpression or constitutive phosphorylation of HER3 can lead to significant resistance to 61 
EGFR-TKIs by activation of downstream PI3K/AKT pathways, which is independent of EGFR 62 
kinase activity [11, 12]. Moreover, abnormal activation of c-Met was significantly associated with 63 
poor response to EGFR-TKIs treatment, regardless of the EGFR status in NSCLC patients [13, 64 
14]. A randomized phase II trial has demonstrated that dual inhibition of EGFR and c-Met can 65 
overcome resistance of EGFR-TKIs and improve outcomes in the MET-positive NSCLC patients 66 
[15, 16]. However, the mechanisms responsible for intrinsic resistance and other acquired 67 
resistance to EGFR-TKI are not fully understood. 68 
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DEAD box helicase 17 (DDX17) belongs to the DEAD box family of RNA helicases and is a 69 
transcriptional co-regulator required for the action of diverse transcription factors that are critical 70 
for normal biologic processes as well as cancer development [17]. DDX17 coactivates oestrogen 71 
receptor alpha (ERα) and is required for oestrogen-dependent expression of ERα-responsive 72 
genes and breast cancer cell growth [18]. Furthermore, DDX17 dysregulation is associated with 73 
the tumorigenesis of meibomian cell carcinoma [19]. In mouse mammary tumor cells, DDX17 74 
regulates the alternative splicing of the chromatin-binding factor macroH2A1 histone gene, 75 
leading to transcriptional alterations to a set of genes involved in redox metabolism [20]. 76 
Additionally, DDX17 subunit in the mouse Drosha complex is indispensable for survival in mice 77 
and is required for primary miRNA and rRNA processing [21]. However, the role of DDX17 in the 78 
susceptibility to EGFR-TKIs in NSCLC cells remains unknown.  79 
In the present study, we provided the first evidence that increased expression of DDX17 in 80 
gefitinib-resistant NSCLC cells than gefitinib-sensitive NSCLC cells. DDX17 downregulation 81 
promotes the apoptosis of gefitinib-resistant NSCLC cells exposed to gefitinib, whereas DDX17 82 
overexpression protects gefitinib-sensitive NSCLC cells against this effect. Mechanistically, we 83 
demonstrate that DDX17 interacts with cytoplasmic β-catenin, facilitates the dissociation of 84 
β-catenin from the E-cadherin/β-catenin complex, enhances β-catenin nuclear accumulation, 85 
subsequently augments the transcription of β-catenin target genes, and ultimately leads to 86 
acquired resistance to gefitinib. Moreover, we found that DDX17 was a nucleocytoplasmic 87 
shuttling protein that was mediated by two NLS and four NES sequence elements. Interrupting 88 
DDX17 nucleocytoplasmic shuttling impairs DDX17-mediated activation of β-catenin and 89 
resistance to gefitinib in NSCLC cells. Taken together, our study highlights the significance of 90 
6 
DDX17 in gefitinib-resistant NSCLC and implicates DDX17 as a potential therapeutic target to 91 
enhance the efficacy of gefitinib in NSCLC patients. 92 
 93 
2. Materials and Methods 94 
2.1 Cell culture and establishment of gefitinib resistant cell lines 95 
A431 and A431-GR cell lines were gifts from Prof. Zeng Cai (Sichuan Provincial People’s 96 
Hospital, China). A549 and A549-GR cell lines were gifts from Prof. Feng Bi (Sichuan University, 97 
China). HCC827 and PC9 NSCLC cell lines were maintained at 37°C and 5% CO2 in RPMI 1640 98 
supplemented with 10% fetal bovine serum (Gibco) and 100 units/ml penicillin, and 100 mg/ml 99 
streptomycin. To establish gefitinib resistant cell lines, parental cells were exposed to gradually 100 
elevated concentrations of gefitinib for two months as reported previously [13, 22].  101 
  102 
2.2 Reagents 103 
Gefitinib and XAV-939 were purchased from Selleck chemicals, and recombinant human 104 
EGF was purchased from PeproTech. The primary antibodies included AKT (Cell signalling 105 
Technology, #4691), p-AKT (Ser473) (Cell signalling Technology, #4060), cleaved caspase-3 (Cell 106 
Signaling Technology, #9664), cleaved PARP (Cell signalling Technology, #5625), DDX17 (Santa 107 
Cruz Biotechnology, sc-271112), E-cadherin (Abcam, ab1416), EGFR (Cell signalling Technology, 108 
#4267), p-EGFR (Tyr1068) (Cell signalling Technology, #3777), ERK (Cell signalling Technology, 109 
#9102), p-ERK (Thr202/Tyr204) (Cell signalling Technology, #4370), Flag (Cell signalling 110 
Technology, #8146), Ki67 (Abcam, ab15580), KPNA1 (Sangon Biotech, D154120), KPNB1 111 
(Sangon Biotech, D161792), PCNA (Santa Cruz Biotechnology, sc-56), XPO1 (Sangon Biotech, 112 
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D221884), α-Tubulin (Santa Cruz Biotechnology, sc-5286), β-actin (Santa Cruz Biotechnology, 113 
sc-47778), β-catenin (Abcam, ab32572), p-β-Catenin (Ser33/37/Thr41) (Cell signalling 114 
Technology, #9561).  115 
 116 
2.3 Stable cell line generation for DDX17 knockdown or overexpression  117 
The DDX17 lentiviral expression vector was constructed by inserting expanded DDX17 cDNA 118 
(NM_006386.4) fragments into a lentiviral shuttle vector. DDX17 knockdown was accomplished 119 
using a specific shRNA targeting DDX17. The shRNA sequences were as follows: shRNA-DDX17, 120 
5’-CAA GGG UAC CGC CUA UAC C-3’; shRNA-NC, 5’-TTC TCC GAA CGT GTC AGG T-3’. The 121 
packing and purification of the recombinant lentiviral vector were performed by the GenePharma 122 
Company (Shanghai, China). The indicated NSCLC cells infected with the recombinant lentiviral 123 
vectors were selected with puromycin for 2 weeks. 124 
 125 
2.4 RNA extraction and real-time PCR  126 
Total RNA was extracted using RNAiso Plus (TAKARA) according to the manufacturer’s 127 
instructions. Real-time PCR was performed with SYBR
®
 Premix Ex Taq™ II (TAKARA) using an 128 
iCycler iQ
TM
 Multicolor Real-Time Detection System (BIO-RAD) as previously described [23, 24]. 129 
The following primers were used: DDX17 forward 5’-GAACATCCGGAAGTAGCAAGG-3’, reverse 130 
5’-GATCCATCAACACATCCATTACATAT-3’; GAPDH forward 5’-ACCACAGTCCATGCCATCAC-3’, 131 
reverse 5’-TCCACCACCCTGTTGCTGTA-3’. The relative expression levels were determined 132 
using Gene Expression Macro Version 1.1 software (BIO-RAD). 133 
 134 
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2.5 TOP/FOP flash assay 135 
For cotransfection, the indicated NSCLC cells were transfected with TOPflash plasmid plus 136 
pRL-TK plasmid or FOPflash plasmid plus pRL-TK plasmid in 48-well plates. Twenty-four hours 137 
post-transfection, the cells were rinsed twice with PBS and then lysed in Passive Lysis Buffer, and 138 
the dual-luciferase reporter assay was performed according to the manufacturer’s instructions 139 
(Promega) using a Multi-Mode Microplate Reader (Synergy 2, BioTek). 140 
 141 
2.6 In vivo assays for tumor growth  142 
Female BALB/c nude mice (6-week-old) were raised in specific pathogen-free conditions. 143 
Animal care and experimental protocols were in accordance with guidelines established by the 144 
Institutional Animal Care and Use Committee of Sichuan University. The indicated NSCLC cells 145 
were suspended in 150 μL serum-free DMEM and implanted subcutaneously into the right flanks 146 
of nude mice. When subcutaneous tumor reached approximately 100 mm
3
, the tumor-bearing 147 
mice were treated with gefitinib (10 mg/kg/day, by a gavage) for 15 days. The tumor volumes were 148 
measured by calipers every 3 days, and calculated using the following formula: tumor volume 149 
(mm
3) = π/6 × length × width2.  150 
  151 
2.7 Statistical analysis 152 
All the experiments were performed at least three times independently, and all data are 153 
expressed as “mean ± SD”. A one-way ANOVA test was used to analyse quantitative data 154 
between groups. The data were analyzed using SPSS statistical software version 22.0. P < 0.05 155 
was considered statistically significant. 156 
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 157 
3. Results 158 
3.1 Upregulation of DDX17 correlates with gefitinib resistance in NSCLC cells 159 
To explore the role of DDX17 in the acquired resistance to gefitinib, we first evaluated the 160 
expression of DDX17 in different NSCLC cell lines. As shown in Figure 1A, the level of DDX17 161 
was markedly higher in gefitinib-insensitive NSCLC cell lines (PC9-GR and HCC827-GR) than 162 
that in gefitinib-sensitive NSCLC cell lines (PC9 and HCC827), respectively. A similar pattern of 163 
increased DDX17 expression level was observed in A549-GR and A431-GR cells compared with 164 
their parental A549 and A431 cells (Supplementary Figure S1). These data suggest that DDX17 165 
may be positively correlated with gefitinib resistance in NSCLC cells. Next, we engineered stable 166 
upregulation of DDX17 expression in gefitinib-sensitive PC9 and HCC827 cells, and stable 167 
shRNA-mediated knockdown of DDX17 in gefitinib-insensitive PC9-GR and HCC827-GR cells 168 
(Figure 1B and Supplementary Figure S2A). Enforced DDX17 expression significantly increased 169 
the cell viability of PC9 and HCC827 cells in response to gefitinib (Figure 1C), whereas 170 
DDX17-silenced cells partially restored gefitinib sensitivity of PC9-GR and HCC827-GR cells 171 
(Supplementary Figure S2B). Moreover, upregulated DDX17 enhanced the resistance to gefitinib 172 
in PC9 and HCC827 cells compared to negative controlled cells (Figure 1D). Consistent with the 173 
MTT assay results, the colony formation in DDX17 overexpression NSCLC cells was significantly 174 
more compared to Mock cells (Figure 1E). The converse results were observed in 175 
DDX17-deficient NSCLC cells (Supplementary Figure S2C). Gefitinib treatment reduced p-EGFR 176 
and downstream signaling proteins p-Akt and p-ERK expressions, and meanwhile increased the 177 
levels of two apoptosis markers, cleaved caspase 3 and cleaved PARP (Figure 1F). However, the 178 
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upregulation of DDX17 partially overcame the gefitinib-inhibited EGFR, AKT and ERK activation, 179 
and suppressed cell apoptosis (Figure 1F). Conversely, knockdown of DDX17 caused decreased 180 
phosphorylation of EGFR, AKT and ERK, while increased expression of cleaved caspase 3 and 181 
cleaved PARP in gefitinib-resistant NSCLC cells treated with gefitinib (Supplementary Figure 182 
S2D). Taken together, our data indicate that DDX17 contributes to the development of acquired 183 
drug resistance to gefitinib in NSCLC cells. 184 
 185 
3.2 DDX17 disassociates the E-cadherin/β-catenin complex and promotes β-catenin nuclear 186 
translocation  187 
Recent evidence indicates that constitutive activation of Wnt/β-catenin signalling is 188 
associated with the acquired drug resistance to EGFR-TKIs in NSCLC [25-27]. To understand the 189 
molecular mechanism by which DDX17 promotes gefitinib resistance, we explored the effect of 190 
DDX17 on the nuclear translocation and activation of β-catenin. As shown in Figure 2A, β-catenin 191 
was located primarily in the plasma membrane in Mock PC9 cells; however, upregulated DDX17 192 
led to the nuclear accumulation of β-catenin. Next, we evaluated the phosphorylation status of 193 
β-catenin. Consistently, phosphorylation of the residues that target β-catenin for proteasomal 194 
degradation (S33/S37/T41) was reduced in response to DDX17 overexpression (Figure 2B). 195 
Conversely, DDX17 knockdown significantly inhibited the levels of nuclear β-catenin in PC9-GR 196 
cells (Figure 2C). EGF, a potent activator of Wnt/β-catenin signalling as described previously 197 
[28-30], promotes β-catenin nuclear translocation in PC9-GR cells, however, DDX17 deletion 198 
markedly repressed the increased nuclear accumulation of β-catenin induced by EGF (Figure 2C). 199 
TOP/FOP-Flash assay showed that down-regulation of DDX17 impaired the transcriptional 200 
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activity of β-catenin/T-cell factor (TCF) complex regardless of EGF treatment (Figure 2D). 201 
Moreover, we found increased nuclear localization of β-catenin as well as decreased p-β-catenin 202 
(S33/S37/T41) in PC9-GR cells compared with PC9 cells (Supplementary Figure S3). 203 
Beta-catenin bound to the E-cadherin/catenin adhesion complex is mainly localizes to cell-cell 204 
adherent junctions at membranes lacking Wnt signalling, and Wnt signalling promotes the 205 
disassociation of E-cadherin/β-catenin complex and subsequently β-catenin nuclear translocation. 206 
Therefore, we next assessed whether DDX17 influenced E-cadherin/β-catenin complex stability. 207 
As shown in Figure 2E, overexpression of DDX17 downregulated E-cadherin/β-catenin complex 208 
formation, whereas knockdown of DDX17 augmented the association of β-catenin and E-cadherin. 209 
Considering the role of DDX17 in the nuclear accumulation and activation of the β-catenin, we 210 
next explored whether DDX17 can interact with β-catenin. Reciprocal immunoprecipitation studies 211 
revealed that endogenous DDX17 bound to endogenous β-catenin directly (Figure 2F). Moreover, 212 
increased interaction between DDX17 and β-catenin was observed in response to EGF stimulus, 213 
whereas EGF repressed β-catenin binding to E-cadherin (Figure 2G). Notably, we found that 214 
DDX17 predominantly interacted with β-catenin in the cytoplasm and that EGF enhanced both the 215 
cytoplasmic and nuclear interaction of β-catenin with DDX17 in a time-dependent manner (Figure 216 
2H). To further investigate whether DDX17-regulated gefitinib resistance involves β-catenin 217 
activation, a specific Wnt/β-catenin signalling pathway inhibitor (XAV-939) was used. XAV-939 218 
treatment effectively reversed DDX17-induced gefitinib resistance in PC9 and HCC827 cells 219 
(Figure 2I), leading to the increased levels of cleaved caspase 3 and cleaved PARP (Figure 2J). 220 
These data indicate that elevated DDX17 level leads to release and nuclear translocation of 221 
β-catenin from the E-cadherin/β-catenin complex and thereby resulting in the activation of 222 
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Wnt/β-catenin signalling and acquired resistance to gefitinib.  223 
 224 
3.3 Two NLSs mediated DDX17 nuclear transport by an importin-dependent pathway 225 
Because DDX17 interacted with β-catenin in the cytoplasm and nucleus, we presumed that 226 
DDX17 might be a nucleocytoplasmic shuttling protein. To test this hypothesis, we first examined 227 
the sublocalization of DDX17 in PC9 and PC9-GR cells using an immunofluorescence assay. 228 
Interestingly, DDX17 was predominantly localized to the nucleus in PC9 cells, whereas DDX17 229 
was present in the cytoplasm and nucleus in PC9-GR cells (Supplementary Figure S2A). 230 
Immunoblotting analysis also showed that more DDX17 was accumulated in both the cytoplasmic 231 
and nuclear fractions of PC9-GR cells than of PC9 cells (Supplementary Figure S2B). These 232 
results indicate that DDX17 may be a nucleocytoplasm shuttling protein.  233 
Most nucleocytoplasm shuttling proteins carry sequence elements of both nuclear 234 
localization signal (NLS) and (nuclear exporting signal) NES. We analysed the DDX17 amino acid 235 
sequence and identified two putative NLSs based on cNLS Mapper analysis 236 
(http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) (Figure 3A). Because the 237 
classical NLSs rich in basic amino acids are known as NLSs recognized by importin, we 238 
generated mutations in NLS1 (K50A, K53A, R74A, R75A, K76A and K77A) or NLS2 (K349A, 239 
R350A and R351A) of DDX17 fused with a GFP fluorescent protein. As shown in Figure 3B, the 240 
DDX17-WT protein showed both cytoplasmic and nuclear fluorescence. However, the NLS 1 241 
mutant showed strong cytoplasmic fluorescence, and the NLS 2 mutant exhibited a complex 242 
distribution in both the nucleus and cytoplasm (Figure 3B). Moreover, no significant nuclear 243 
localization of DDX17 was observed in NLS mutant (NLS M, mutated both NLS 1 and NLS 2) 244 
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(Figure 3B). The similar result was also confirmed by immunoblot analyses (Figure 3C). As the 245 
nuclear transport of most nucleocytoplasmic proteins is mediated by importin complex which 246 
formed a hetero-dimer, we next explored whether DDX17 interacts with importin. Reciprocal 247 
immunoprecipitation studies revealed that endogenous DDX17 co-precipitated with endogenous 248 
KPNA1 (also known as Importin subunit alpha-5) and KPNB1 (also known as Importin subunit 249 
beta-1) (Figure 3D). However, DDX17 NLS mutant did not co-precipitate with KPNA1 and KPNB1 250 
(Figure 3E). To further determine whether importin signalling mediated DDX17 nuclear 251 
localization, we treated cells with Ivermectin, which is a potent inhibitor of importin α/β-dependent 252 
transport [31, 32]. As shown in Figure 3F, ivermectin treatment caused the main cytoplasmic 253 
fluorescence of GFP-DDX17 fusion protein. Similarly, immunoblot analysis also showed the 254 
decreased nuclear accumulation of DDX17 in the presence of ivermectin (Figure 3G). Notably, 255 
ivermectin blocked the association of DDX17 with importin complex (Figure 3H). These data 256 
indicate that two NLSs of DDX17 recognized by importin complex mediated DDX17 nuclear 257 
transport.  258 
 259 
3.4 Four NESs mediated DDX17 nuclear export by an exportin-dependent pathway 260 
For the classical nuclear export pathway, XPO1 binds directly hydrophobic residue-rich 261 
NES sequence in the cargo protein and directs the export of the complex from the nucleus [33]. 262 
According to this theory, we found four putative NESs in DDX17 and constructed a series of site 263 
directed mutagenesis fused to the C-terminus of GFP (Figure 4A). As shown in Figure 4B, both 264 
cytoplasmic and nuclear localizations of DDX17-WT protein were observed in PC9 cells. The NES 265 
1 mutant (L144A, L147A, L148A, I151A, V152A and I154A), NES 2 mutant (L226A, I227A, F229A, 266 
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L230A, L237A, L243A, V244A, L245A) and NES 3 mutant (V284A, L284A, L292A, Y295A, I298A, 267 
L303A, L305A) showed major nuclear localization, whereas mutations on NES 4 (L448A, L454A, 268 
I455A, V457A, L458A) localized in dispersed subnuclear speckles (Figure 4B). In addition, a 269 
complete NES mutant (mutated all four NESs) resulted in exclusive nuclear localization of DDX17, 270 
suggesting that these four NESs function as DDX17 nuclear export signals (Figure 4B). 271 
Immunoblot analysis also confirmed the subcellular localization of DDX17-WT and DDX17 NES 272 
mutant (Figure 4C). To confirm the effects of XPO1 on export of DDX17, we probed the interaction 273 
between DDX17 and XPO1 via co-immunoprecipitation. It was clear that endogenous DDX17 274 
co-immunoprecipitated with endogenous XPO1 (Figure 4D). In addition, we found that the DDX17 275 
NES mutant impaired the binding of DDX17 and XPO1 (Figure 4E). To further verify that the 276 
DDX17 cytoplasmic shuttling is mediated by XPO1, PC9 cells were treated with leptomycin B 277 
(LMB), a potent and specific nuclear export inhibitor. LMB effectively suppressed the level of 278 
cytoplasmic DDX17 in PC9 cells (Figures 4F and 4G). Moreover, LMB treatment significantly 279 
disrupted the interaction between DDX17 and XPO1 (Figure 4H). These observations suggest 280 
that four NESs are required for DDX17 cytoplasmic shuttling mediated by the classical 281 
exportin-dependent pathway.  282 
 283 
3.5 The integrity of DDX17 nucleocytoplasmic shuttling is indispensable for mediating the 284 
acquired resistance and activation of β-catenin 285 
We next evaluated the impact of DDX17 nucleocytoplasmic shuttling on cellular resistance 286 
to gefitinib. As shown in Figure 5A, ectopic expression of DDX17-WT significantly increased the 287 
cell viability of PC9 and HCC827 cells upon gefitinib treatment. The decreased resistances to 288 
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gefitinib were observed in DDX17-NLS mutant and DDX17-NES mutant PC9 cells compared to 289 
DDX17-WT PC9 cells, respectively (Figure 5A). Interestingly, DDX17-NLS mutant PC9 cells 290 
showed a similar sensitivity as mock PC9 cells, whereas DDX17-NES mutant PC9 cells were 291 
more resistant to gefitinib than mock PC9 cells (Figure 5A). Consistently, less colony formations 292 
were found in DDX17-NLS mutant and DDX17-NES mutant PC9 cells than DDX17-WT PC9 cells 293 
(Figure 5B). The immunoblotting test showed that cleaved caspase 3 and cleaved PARP were 294 
significantly enhanced in both DDX17-NLS mutant and DDX17-NES mutant PC9 cells compared 295 
to DDX17-WT PC9 cells (Figure 5C). To further determine the effect of DDX17 nucleocytoplasmic 296 
shuttling on the gifitinib resistance in vivo, indicated PC9 cells were injected subcutaneously into 297 
the flanks of BALB/c nude mice. Overexpression of DDX17-WT exerted obvious gefitinib 298 
insensitivity in tumor xenografts model compared to mock xenografts in the present of gefitinib (10 299 
mg/kg per day, gavaged orally) (Figure 5D). However, DDX17-NLS mutant and DDX17-NES 300 
mutant xenografts was partially rescued gefitinib sensitivity compared with DDX17-WT xenografts 301 
(Figure 5D). The primary tumors from the DDX17-WT xenografts exhibited increased expression 302 
of Ki67 while decreased expression of cleaved caspase 3 compared with tumors originating from 303 
DDX17-NLS mutant and DDX17-NES mutant xenografts (Figure 5E).  304 
Based on the aforementioned observations, we became interested in exploring the effect of 305 
DDX17 nucleocytoplasmic shuttling on the activation of β-catenin. As shown in Figure 6A, DDX17 306 
NLS mutant showed a comparable association of β-catenin, whereas DDX17 NES mutant 307 
showed a slightly decreased association of β-catenin compared with DDX17 WT. DDX17 WT and 308 
DDX17 NLS mutant caused significant disassociation of E-cadherin/β-catenin complex, however, 309 
DDX17 NES mutant displayed modest inhibition of the interaction between β-catenin and 310 
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E-cadherin compared to control (Figure 6B). Moreover, less nuclear β-catenin was observed in 311 
the DDX17 NLS mutant and NES mutant group compared to that of the wild type (Figure 6C). In 312 
addition, DDX17 NLS mutant and NES mutant groups showed significantly decreased luciferase 313 
activity compared to wild type (Figure 6D). Overall, the above experiments suggest that 314 
interruption of DDX17 nucleocytoplasmic shuttling impairs DDX17-mediating the acquired 315 
resistance and activation of β-catenin in NSCLC cells.  316 
 317 
4. Discussion 318 
EGFR-mutant NSCLC patients who benefited from EGFR-TKI eventually develop acquire 319 
resistance to these therapies and the median duration of response is about 10 to 14 months [34, 320 
35]. Although accumulating studies revealed that a variety of mechanisms can stimulate acquired 321 
resistance to EGFR-TKI including secondary mutations within EGFR at position T790, activation 322 
of parallel receptor tyrosine kinases (such as ALK, MET and RET), and mutation or upregulation 323 
of EGFR effector proteins [36-38], the mechanisms responsible for acquired resistance to 324 
EGFR-TKIs are still large unknown. In this study, we showed that DDX17 levels were increased in 325 
gefitinib resistant cells compared with gefitinib sensitive cells. Overexpression of DDX17 326 
significantly increased tolerance of PC9 and HCC827 cells in the present of gefitinib, whereas 327 
DDX17 suppression resulted in reduced cell viability of gefitinib-resistant PC9-GR and 328 
HCC827-GR cells. These data revealed that DDX17 expression was associated with tumor 329 
sensitivity to gefitinib in NSCLC cells.  330 
The Wnt/β-catenin signaling is one of the most critical signaling transduction pathways 331 
during embryonic development and the stemness maintenance, and has become a hot topic in 332 
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tumor research [39, 40]. In recent years, accumulating evidence reported that Wnt/β-catenin 333 
signalling has been implicated in the chemoresistance of varied cancers [41, 42]. Here, we 334 
demonstrated that DDX17 directly bound and dissociated the E-cadherin/β-catenin complex to 335 
release β-catenin, subsequently leading to β-catenin nuclear accumulation. Moreover, we found 336 
that EGF augmented the interaction between β-catenin and DDX17 both in the cytoplasm and 337 
nucleus, whereas DDX17 repression abolished the EGF-induced nuclear translocation and 338 
activation of β-catenin. Therefore, we postulated that DDX17-dependent nuclear accumulation of 339 
β-catenin released from the E-cadherin/β-catenin adhesion complex was an important 340 
mechanism driving acquired resistance to gefitinib in NSCLC cells.  341 
To enhance cytoplasmic β-catenin nuclear translocation, DDX17, which is predominantly 342 
localized in the nucleus [43], must shuttle to the cytoplasm. Interestingly, increased DDX17 levels 343 
were observed in both the cytoplasmic and nuclear fractions of PC9-GR cells than of PC9 cells. 344 
Moreover, DDX17 interacted with β-catenin both in the cytoplasm and nucleus. These data 345 
supported DDX17 as a nucleocytoplasmic protein. Most nucleocytoplasmic protein movement 346 
through the nuclear pore complex is mediated by a nuclear receptor system [44, 45]. In this study, 347 
we identified two NLSs and four NESs required for DDX17 nucleocytoplasmic shuttling. Mutation 348 
of the NLSs significantly inhibited the DDX17 nuclear localization and association of DDX17 and 349 
import complex. Analogously, NESs mutant caused nuclear accumulation of DDX17 and 350 
disrupted the interaction between DDX17 and XPO1. These results indicated that the 351 
nucleocytoplasmic shuttling of DDX17 followed a classical exportin/importin-dependent pathway. 352 
Interestingly, several DEAD box RNA helicases shuttle between the nucleus and cytoplasm via 353 
XPO1-dependent nuclear export pathway, including DDX3, DDX25, and DDX48 [46-48]. 354 
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Furthermore, block of DDX17 nucleocytoplasmic shuttling significantly reduced DDX17-mediated 355 
activation of β-catenin and gefitinib sensitivity in NSCLC cells, suggesting that dynamic 356 
nucleocytoplasmic shuttling of DDX17 is essential for its function. Interestingly, a decreased 357 
tolerance was observed in DDX17-NES mutant cells compared with DDX17-WT cells, however, 358 
DDX17-NES mutant cells were more resistant to gefitinib than mock PC9 cells. Because DDX17 359 
can act as co-transcriptional regulator, one possible explanation is that nuclear DDX17 regulated 360 
the transcription of target genes that lead to the activation of Wnt/β-catenin signalling independent 361 
cytoplasmic function of DDX17. Although DDX17-NLS mutant has no significant effect on the 362 
association of DDX17 and β-catenin, the nuclear accumulation of β-catenin was depressed in 363 
DDX17-NLS mutant cells compared with DDX17-WT cells. Considering the main interaction of 364 
DDX17 and β-catenin in the cytoplasm, we presume that DDX17 might function as a ‘chaperone’ 365 
to aid β-catenin nuclear import; however, the detailed mechanism requires further exploration.  366 
In summary, our study provides the first evidence that upregulated DDX17 expression is 367 
associated with gefitinib resistance in NSCLC cells and DDX17 is a nucleocytoplasmic protein 368 
mediated by two NLSs and Four NESs. We demonstrate a new molecular mechanism by which 369 
the exportin/importin-dependent nucleocytoplasmic translocation of DDX17 disassociates the 370 
E-cadherin/β-catenin complex, resulting in β-catenin nuclear translocation and subsequently 371 
augmenting the transcription of β-catenin target genes, ultimately driving gefitinib resistance in 372 
NSCLC cells. Interruption of dynamic nucleocytoplasmic shuttling of DDX17 impairs 373 
DDX17-mediating the activation of β-catenin and acquired resistance in NSCLC cells. In 374 
conclusion, we propose that DDX17 is an attractive and potential target for overcoming gefitinib 375 
resistance in NSCLC therapy 376 
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8. FIGURE LEGENDS 551 
8.1 Figure 1. Upregulated DDX17 is associated with gefitinib resistance in human NSCLC 552 
cells. (A) Quantitative real-time PCR and immunoblot analysis of DDX17 expression in gefitinib 553 
sensitive and insensitive NSCLC cells. (B) Quantitative real-time PCR and immunoblot analysis 554 
showed the successful lentiviral infections of DDX17 in PC9 and HCC827 cells. (C) Stably 555 
expressing DDX17 or mock NSCLC cells were treated with 1 μM gefitinib for indicated time and 556 
analyzed for cell viability by MTT assay. (D) Effect of DDX17 overexpression on gefitinib efficacy 557 
in HCC827 and PC9 cells was detected by MTT assay. (E) Representative photographs of the 558 
colony formation of indicated NSCLC cells treated with gefitinib for 14 days after culture of cells. 559 
(F) The indicated NSCLC cells were treated with or without gefitinib and then subjected to 560 
immunoblot analysis using the indicated antibodies. Data represent the mean ± standard 561 
deviation (SD). Each experiment was performed at least in triplicate, producing consistent results. 562 
*P < 0.05. 563 
 564 
8.2 Figure 2. DDX17 disassociates the E-cadherin/β-catenin complex and promotes 565 
β-catenin nuclear translocation. (A) Immunofluorescence analysis of β-catenin (red) in 566 
indicated PC9 cells. Merged images represent overlays of β-catenin (red) and nuclear staining by 567 
DAPI (blue). (B) Immunoblotting for phosphorylated β-catenin (S33/S37/T41) in indicated PC9 568 
cells. (C) Immunoblotting for β-catenin in the nuclear extracts of indicated PC9-GR cells in the 569 
present of EGF. PCNA was used as the control. (D) TOP/FOP flash assay in the indicated 570 
PC9-GR cells treated with or without EGF. (E) The effect of DDX17 on the association of β-catenin 571 
with E-cadherin was detected by western blot analysis. (F) The endogenous interaction of DDX17 572 
29 
and β-catenin was detected by immunoprecipitation with indicated antibodies. (G) The impact of 573 
EGF on the interaction of DDX17 and β-catenin/E-cadherin complex. (H) The cytoplasmic and 574 
nuclear extracts of PC9-GR cells stimulated with EGF were isolated. Immunoprecipitation were 575 
performed with anti-DDX17 antibody. α-Tubulin and PCNA were control. (I) Effect of XAV-939 on 576 
gefitinib efficacy in indicated NSCLC cells was detected by MTT assay. (J) The indicated NSCLC 577 
cells were treated with gefitinib in the presence or absence of XAV-939, and then subjected to 578 
immunoblot analysis using the indicated antibodies. Data represent the mean ± SD of three 579 
independent experiments. *P < 0.05. 580 
 581 
8.3 Figure 3. Two NLSs mediated DDX17 nuclear transport by an importin-dependent 582 
pathway. (A) Putative sequence segments of DDX17 NLSs. (B) Representative of fluorescent 583 
microscopy images show the localizations of the exogenously expressed DDX17 wild type (WT) 584 
and putative NLSs mutants fused with GFP in PC9 cells. (C) The levels of exogenously expressed 585 
DDX17 WT or NLS mutant in the extracts made from the cytoplasm or the nucleus of PC9 cells 586 
were examined by immunoblotting analysis. PCNA and α-Tubulin were used as the control. (D) 587 
The endogenous association of DDX17 and importin complex was detected by 588 
immunoprecipitation with indicated antibodies. (E) The impact of NLS mutant on the interaction 589 
between DDX17 and importin complex. (F) Representative of fluorescent microscopy images 590 
show the sub-localizations of DDX17 in PC9 cells treated with or without ivermectin. (G) The 591 
effect of Ivermectin on the distribution of DDX17 was performed by western blot analysis in PC9 592 
cells. (H) The effect of Ivermectin on the binding of DDX17 and importin complex. Data represent 593 
the mean ± SD of three independent experiments. 594 
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 595 
8.4 Figure 4. Four NESs mediated DDX17 nuclear export by an exportin-dependent pathway. 596 
(A) Putative sequence segments of DDX17 NESs. (B) Representative of fluorescent microscopy 597 
images show the localizations of the exogenously expressed DDX17 WT and putative NESs 598 
mutants fused with GFP in PC9 cells. (C) Immunoblotting for DDX17 in PC9 cytoplasmic and 599 
nuclear extracts of cells transfected with the indicated plasmids. PCNA and α-Tubulin were used 600 
as the control. (D) The endogenous association of DDX17 and XPO1 was detected by 601 
immunoprecipitation with indicated antibodies. (E) The impact of NES mutant on the interaction 602 
between DDX17 and XPO1. (F) Representative of fluorescent microscopy images show the 603 
sub-localizations of DDX17 in PC9 cells treated with or without LMB. (G) The effect of LMB on the 604 
distribution of DDX17 was performed by western blot analysis in PC9 cells. (H) The effect of LMB 605 
on the binding of DDX17 and XPO1. Data represent the mean ± SD of three independent 606 
experiments. 607 
 608 
8.5 Figure 5. Interruption of DDX17 nucleocytoplasmic shuttling impairs DDX17-mediated 609 
gefitinib resistance in vitro and in vivo. (A) Indicated NSCLC cells were treated with varied 610 
concentration of gefitinib, and the cell viability were analysed by MTT assay. (B) Representative 611 
photographs of the colony formation of indicated NSCLC cells treated with gefitinib for 14 days 612 
after culture of cells. (C) The indicated NSCLC cells were treated with gefitinib and then subjected 613 
to immunoblot analysis using the indicated antibodies. (D) The indicated NSCLC cells were 614 
transplanted into nude mice. When subcutaneous tumor reached approximately 100 mm
3
, the 615 
tumor-bearing mice were treated with gefitinib (10 mg/kg/day, by a gavage) for 15 days. The 616 
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tumor volumes were measured by calipers every 3 days. (E) Tumor xenograft tissues were fixed 617 
with 4% paraformaldehyde, processed, embedded in paraffin wax and then assessed for 618 
immunohistochemical analyses with indicated antibodies. Data represent the mean ± SD of three 619 
independent experiments. *P < 0.05.  620 
 621 
8.6 Figure 6. The integrity of DDX17 nucleocytoplasmic shuttling is essential for 622 
DDX17-mediating the activation of β-catenin in NSCLC cells. (A) The impact of NLS mutant 623 
and NES mutant on the interaction of DDX17 and β-catenin. (B) The effect of NLS mutant and 624 
NES mutant on the association of E-cadherin/β-catenin complex. (C) Immunoblotting for β-catenin 625 
in the nuclear extracts of indicated PC9 cells. PCNA was used as the control. (D) TOP/FOP flash 626 
assay were performed in the indicated PC9 cells. Data represent the mean ± SD of three 627 
independent experiments. *P < 0.05. 628 
